Filing Flows › Health Care › Actinium Pharmaceuticals (ATNM)
Actinium Pharmaceuticals (ATNM) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 7, 2026 · Actinium Pharmaceuticals (ATNM) Q2 2026 earnings results →
Q2 2026 80¢ of every $1 of revenue kept as net profit · operating margin 78.8%
Actinium Pharmaceuticals made $35.0M in Q2 2026. Operating margin 78.8%, net earnings $27.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 7, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $35.0M in Q2 2026.
Operating profit was $27.6M, a 78.8% margin. Net earnings were $27.9M. The effective tax rate was 0.0%.
Operating cash flow was −$5.2M. Non-cash charges added back $432K of depreciation and amortization and $118K of share-based compensation. Working capital and other items used $33.6M. Capital expenditures of $478K exceeded it, leaving free cash flow of −$5.7M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 7, 2026 | $35.0M | — | 78.8% | $27.9M | −$5.2M |
| Q3 2025 | 10-Q | Nov 14, 2025 | $90K | — | n/m | −$5.1M | −$6.3M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Actinium Pharmaceuticals
We are a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology. We are focused on employing a biology-driven approach to develop differentiated, first-in-class radiopharmaceutical therapeutics for patients with solid tumors and hematologic malignancies. Our mission is to transform cancer treatment by delivering innovative radioconjugates that maximize therapeutic efficacy while minimizing toxicity to healthy tissue by combining our deep understanding of tumor biology and translational medicine with our expertise in radiochemistry.
In its own words, from its 10-K, filed Mar 30, 2026.
Actinium Pharmaceuticals against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Operating margin: 78.8% against the peers' median 30.7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ATNM Actinium Pharmaceuticals | Q2 2026 | $35.0M | — | 78.8% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Actinium Pharmaceuticals 10-Q on SEC EDGAR · CIK 1388320 · Pharmaceutical Preparations
13F: who owns ATNM and who is buying
More on ATNM
History
Every quarter: Q2 2026 results · Q3 2025 results